Drug updated on 3/28/2024
| Dosage Form | Injection (subcutaneous; 300 units/3 mL, 600 units/3 mL, 1000 units/10 mL) |
| Drug Class | Long-acting human insulin analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- To improve glycemic control in patients 1 year of age and older with diabetes mellitus.
Summary
- Insulin degludec (Tresiba) is indicated for improving glycemic control in patients 1 year of age and older with diabetes mellitus.
- A total of 20 systematic reviews/meta-analyses were reviewed to gather information about insulin degludec (Tresiba).
- Compared to Neutral Protamine Hagedorn (NPH) insulin, both insulin degludec and insulin glargine U-100 have been found effective in achieving glycemic control with fewer hypoglycemic events.
- In comparison to other long-acting insulins such as glargine U-300, detemir, and glargine U-100, the use of Tresiba resulted in comparable or slightly better outcomes regarding fasting plasma glucose levels among type 1 and type 2 diabetes mellitus patients.
- The risk of nocturnal hypoglycaemia was lower when using Tresiba compared to other analogues like IGlar; this advantage extended across both Type 1 & Type 2 diabetic populations.
- Among all the long acting insulins studied including Degludec (Gla), Detemir (IDet) showed a favorable weight profile causing less weight gain than others which could be an important consideration for health professionals prescribing these drugs.
- Special considerations are needed while prescribing this drug especially for those who are inadequately controlled on oral anti-diabetic drugs or those who are new users (insulin-naïve); starting doses may need adjustment based on individual patient's needs focusing on their risk factors related to hypoglycaemia episodes & weight management concerns.
- In terms of safety & efficacy amongst Asian population suffering from Type II Diabetes Mellitus (T2DM), no significant differences were observed between different types of long acting insulins including Degludec (Tresiba).
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tresiba (insulin degludec) Prescribing Information. | 2022 | Novo Nordisk Inc., Plainsboro, NJ |